Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: Special emphasis on 'spiking' phenomena

Clinical Biochemistry

Volumn 30, Issue 1, 1997, Pages 53-56

  Yasasever, Vildan ^a   Dinçer, Maktav ^a   Çamlica, Hakan ^a   Karaloǧlu, Derya ^a   Dalay, Nejat ^a  

^a IU Oncology Institute   (Turkey)

Author keywords

bone metastases; breast cancer; CA 15 3; CEA; spiking

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ADULT; ANTIGEN DETECTION; ARTICLE; BONE METASTASIS; BREAST CANCER; CLINICAL ARTICLE; DIAGNOSTIC VALUE; HUMAN; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGNOSIS;

BONE NEOPLASMS; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 0342710341     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(96)00133-6     Document Type: Article

References (16)

1. Bates SE, Longo DL, Use of serum tumor markers in cancer diagnosis and management. Semin Oncol 1987; 14: 102-138.
2. Lüthgens ML, Oehr P, Clinical cancer markers. In: Sell S, Ed. Serological cancer markers. Pp. 19-29. Tolowa: Humana Press, 1992.
3. Liu FJF, Serum tumor marker assays in cancer patient care. Cancer Bull 1993; 45: 55-63.
4. Bombardieri E, Pizzichetta M, Veronesi P, et al., CA 15-3 determination in patients with breast cancer: Clinical utility for the detection of distant metastases. Eur J Cancer 1993; 29A: 144-146.
5. Roisman I, Israeli A, Lifshitz I, et al., The significance of the CA 15-3 breast tumor marker as an additional tool for detection of breast cancer. J Tumor Marker Oncol 1994; 9: 19-24.
6. Eskelinen M, Tikanoja S, Collan Y, Use of tumor markers CA 15-3, MCA and CEA in breast cancer diagnostics. J Tumor Marker Oncol 1989; 4: 39-44.
7. Hilkens J, CA 15-3 Assay for the detection of episialin. In: Sell S, Ed. Serological cancer markers. Pp. 261-280. Tolowa: Humana Press, 1992.
8. Hayes DF, Tondini C, Kufe DW, Clinical Applications of CA 15-3. In; Sell S, Ed. Serological cancer markers. Pp. 281-307. Tolowa: Humana Press, 1992.
9. Hayes DF, Kiang DT, Korzun AH, et al., CA 15-3 and CEA spikes during chemotherapy for metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol 1988; 7: A146.
10. Pons Anicet DMF, Krebs BP, Mira R, Namer MJ, Value of CA 15-3 in the follow-up of breast cancer patients. Br J Cancer 1987; 55: 567-569.
11. Schmidt-Rhode P, Schulz KD, Sturm G, et al., CA 15-3 as a tumor marker in breast cancer. Int J Biol Markers 1987; 2: 135-142.
12. Tandini C, Hayes DF, Gelman R, et al., Comparison of CA 15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 1988; 48: 4107-4112.
13. Aydiner A, Topuz E, Dişçi R, et al., Serum tumor markers for detection of bone metastasis in breast cancer patients. Acta Oncol 1994; 33: 181-186.
14. Colomer R, Ruibal A, Genolla J, et al., Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non malignant diseases. Breast Cancer Res Treat 1989; 13: 123-133.
15. Krein MJ, Mc Anena OJ, O'Malley VP, et al., CA 15-3: Its relationship to clinical stage and progression to metastatic disease in breast cancer. Br J Surg 1989; 76: 838-839.
16. Hayes DF, Kaplan W, Evaluation of patients after primary therapy. In: Harris JR, Lippman ME, Morrow M, Hellman S, Eds. Diseases of the breast. Pp. 629-647. Philadelphia: Lippincott-Raven, 1996.